title: Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study.
abstract: BACKGROUND
  To date, it is unclear whether Helicobacter pylori infection is associated with disturbances of gastric emptying or acid secretion in patients with functional dyspepsia (FD). Our aim was to investigate whether, in the long run, cure of H. pylori infection significantly influences gastric emptying of solids, acid secretion, and gastrin and pepsinogen I (PGI) release in patients with FD.
  
  
  METHODS
  Thirty-eight consecutive H. pylori-positive patients with FD, whose complaints were scored for severity and frequency on the basis of a validated symptom questionnaire, were initially enrolled in the study. They were randomized to receive an eradicating regimen consisting of omeprazole plus clarithromycin and tinidazole for 1 week or full-dose ranitidine for 3 weeks. In 33 patients (18 H. pylori-cured and 15 with persistent infection) basal and pentagastrin-stimulated acid secretion, fasting and meal-induced gastrin concentrations, fasting serum PGI levels, and gastric emptying of solids were determined before and 6 months after therapy.
  
  
  RESULTS
  In the 18 H. pylori-cured patients meal-induced gastrin and fasting PGI levels were significantly reduced after 6 months as compared with pretreatment values (peak serum gastrin, 76.0 +/- 23.4 versus 111.9+/-37.4 pg/ml; PGI, 57.1+/-23.4 versus 72.9+/-29.1 ng/ml), whereas they remained virtually unchanged in the 15 patients with persistent infection. In contrast, both basal and stimulated acid secretion and gastric emptying time of solids remained unmodified over time in both groups of patients.
  
  
  CONCLUSIONS
  We confirm that also in patients with functional dyspepsia H. pylori eradication in the long run significantly reduces gastrin and PGI release as a result of improvement in the underlying antral gastritis, but this is not accompanied by modifications of gastric emptying of solids or acid secretion.
authors.affiliation: Dept. of Gastroenterology and Pathology Service, L. Sacco University Hospital, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Parente
authors.forename: V
authors.initials: V
authors.lastname: Imbesi
authors.forename: G
authors.initials: G
authors.lastname: Maconi
authors.forename: C
authors.initials: C
authors.lastname: Cucino
authors.forename: G
authors.initials: G
authors.lastname: Manzionna
authors.forename: L
authors.initials: L
authors.lastname: Vago
authors.forename: G
authors.initials: G
authors.lastname: Bianchi Porro
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005746:Gastric Emptying / Q000187:drug effects*; D005755:Gastrins / Q000097:blood; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D010435:Pepsinogens / Q000032:analysis; D011446:Prospective Studies; D011899:Ranitidine / Q000008:administration & dosage*; D014011:Tinidazole / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D005755:Gastrins; D010435:Pepsinogens; D014011:Tinidazole; D011899:Ranitidine; D017291:Clarithromycin; D009853:Omeprazole